Note: EPS may not be comparable

Novavax (NASDAQ: NVAX) reported Q4 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $7.98 million.

For earnings history and earnings-related data on Novavax (NVAX) click here.